ELSEVIER

Seminars in Oncology

AUTHOR INDEX

Abou-Alfa, G.K., 347
Aboulafia, A.J., 206
Aboulafia, D., 206
Afrasiabi, K., 425
Albiol, S., 135
Allison, J.P., 165

Bajorin, D.F., 73
Beekman, K.W., 154
Bellmunt, J., 135
Berwick, M., 566
Blackstock, A.W., 327
Blazer III, D.G., 270
Blumenthal, D.T., 197
Bochner, B.H., 110
Bokstein, F., 197
Bordeaux, J.S., 460
Borden, E.C., 449
Bradley, D., 154
Brenner, B., 43
Butler, J., 327
Byzova, T.V., 555

Canto, M.I., 295
Catton, C.N., 256
Chapman, P.B., 516
Chari, S.T., 284
Cooper, A., 226
Cooper, K.D., 460
Cordon-Cardó, C., 75
Crane, C.H., 335
Crowder, S., 57
Crowson, A.N., 476

DeMarco, T.A., 369
Demmy, T.L., 175, 215
Dent, R., 392
DePriest, P., 226
Doll, D., 1
Domchek, S.M., 401
Donat, S.M., 98
Dreicer, R., 145
Dudley, M.E., 524
Dunn, K.B., 241

Eggermont, A.M.M., 509
Eng, C., 428
Evans, D.B., 335
Evans, D.G., 411

Faries, M.B., 498
Fernando, S.A., 129
Floyd, J., 39
Fong, Y., 177
Foulkes, W.D., 379
Frazier, S.R., 30

Gilligan, T., 145
Goggins, M., 303
Gore, M., 509
Gruis, N.A., 452
Gushchin, V., 215
Gustafson, S., 428

Halaban, R., 566
Haluska, F., 546
Herlyn, M., 566
Hill, J., 411
Hurd, T.C., 234
Hussain, M., 154

Ibrahim, N., 546
Isaacs, C., 369

Kalinsky, K., 546
Kane III, J.M., 215
Kanner, A.A., 197
Kaplan, P.A., 30
Karavadia, S.S., 22
Kastrinos, F., 418
Kauff, N.D., 406
Kehoe, S.M., 406
Kelsen, D.P., 43
Kirkwood, J.M., 532
Klimstra, D.S., 43
Ko, A.H., 354
Kuvshinoff, B., 177

Levine, A.M., 206
Lipkin, S.M., 425
Lobitis, R., 39
Loy, T.S., 30
Lu, K.Q., 460

Magro, C., 476
Mahabeleshwar, G.H., 555
Mastrangelo, M.J., 447, 491
McKenna Jr, R.J., 250
McMahon, R.T., 411
Mihm Jr, M.C., 476
Miller, A., 476
Mirza, I.A., 1, 64, 67
Morton, D.L., 498
Mulcahy, M.F., 321

Newton Bishop, J.A., 452
Nusbaum, R.H., 369

O'Donnell, M.A., 85
Offit, K., 435
Old, L.J., 165
O'Reilly, E.M., 347
Ove, R., 327

Palmgren, J.S., 22
Parekh, D.J., 98

Pemberton, T., 546
Peshkin, B.N., 369
Pinkel, D., 566
Pisters, P.W.T., 335

Raj, G.V., 110
Rajput, A., 241
Ram, Z., 197
Reed, R.J., 467
Renner, G., 3
Retsas, S., 491
Robson, M.E., 367, 384
Rodriquez, E., 401
Ronai, Z., 566
Rosenberg, S.A., 524
Rousseau, D., 234
Russo, S., 327

Sabel, M.S., 270
Sánchez-Carbayo, M., 75
Sandler, H.M., 129
Scacheri, C., 428
Schmidt, D., 206
Schuchter, L., 566
Schwartz, M.D., 369
Shahab, N., 1, 15, 64, 67
Sharma, P., 165
Shia, J., 43
Smith, K.L., 369
Sondak, V.K., 270
Sonett, J.R., 186
Sternberg, C.N., 122
Sternberg, D.I., 186
Swallow, C.J., 256
Swann, M.H., 51
Syngal, S., 418

Talamonti, M.S., 311
Tang, L.H., 43
Tawbi, H.A., 532
Tempero, M., 283
Thom, P., 435
Tuller, E., 57
Tuthill, R.J., 467

Ujiki, M.B., 311

Varadhachary, G., 335
Vazquez, B., 234

Wakefield, M.R., 22
Walsh, S., 411
Warner, E., 392
Wolff, R.A., 335

Yoon, J., 51

Zbuk, K.M., 428

ELSEVIER

Seminars in
Oncology

SUBJECT INDEX

Adaptive immunity, in high-risk bladder cancer, 165-166
Adjuvant chemotherapy, for bladder preservation in muscle-invasive bladder cancer, 122-127
Adjuvant therapy
  for gastrointestinal stromal tumor, 245-246
  for rectal cancer, 245-246
Adoptive cell transfer therapy
  for melanoma
    bulk TIL with lympho-depleting preparative regimen, 527-529
    cloned PBL and IVS PBL, 525-527
    lymphokine-activated killer cell and early tumor-infiltrating lymphocyte studies, 524-525
    TCR gene with, 529
AKT pathway, in melanomagenesis, 549
Alkylating agents, for metastatic melanoma, 532-535
Anastomosis, pancreatic-enteric, for surgical management of pancreatic adenocarcinoma, 316
Angiogenesis
  in melanoma, growth factors stimulation in, 556-563
  targeted in pancreatic cancer, 358-359
    bevacizumab, 359
Angiogenesis inhibitors, for advanced urothelial cancer, 157
Anti-folate agents, for advanced pancreatic adenocarcinoma, 350
Autoantibodies, randomized trial in melanoma, 513
Autoimmunity, randomized trial in melanoma, 513

BAY 43-9006 (Sorafenib), for advanced urothelial cancer, 158
bcl-2, in the molecular basis of melanomagenesis and the metastatic phenotype, 479-480
Bevacizumab
  for advanced urothelial cancer, 158
  for targeted pancreatic cancer therapy, 359
Bilharzial bladder carcinoma, management of, 146-147
Biochemotherapy
  for metastatic melanoma, 536-538
    concurrent regimen, 537-538
    sequential chemoimmunotherapy, 537
Bladder, small cell carcinoma of
  clinical features, 16
  diagnosis, 16-17
  epidemiology, 15
  histology, 15-16
  prognosis, 19
  staging, 17
  treatment, 17-19
Bladder cancer
  adjuvant chemotherapy, 125-126
    issues, 126
    meta-analysis, 126
    randomized trials, 126
  bladder preservation and neoadjuvant chemotherapy, 124-125
  clinical presentation and evaluation, 86
  clinicopathologic characteristics and economical impact, 76
  disease-specific progression biomarkers, 76-77
  high-risk, immunotherapy for, 165-171
  high-throughput transcript profiling
    clinical specimens for, 79-82
    in vitro models for, 78-79
Bladder cancer (*Continued*)
  identification of molecular targets with microarray technologies, 77
  improvements in clinical management, enhanced clinical outcomes, molecular alterations targeting treatment of, 73-74
  innate and adaptive immunity, 165-166
  long-term follow-up, 138
  modern double chemotherapy for, 136-137
  molecular predictive factors, 139-140
  multimodality approach for organ preservation in, 130
  multimodality bladder preservation therapy for, 129-133
  multimodality RTOG protocols, 131
  muscle-invasive, perioperative chemotherapy for bladder preservation in, 123-127
    neoadjuvant chemotherapy, 122-123
  M-VAC for, 135-136
  neoadjuvant chemotherapy, 122-123
    issues, 124
    meta-analysis, 124
    randomized trials, 123-124
  new active single agents and doublets for, 136
  oncogenes and tumor-suppressor genes in progression of, 77
  optimal surgical standard of radical cystectomy and lymphadenectomy for
    contemporary lymphadenectomy, 112-114
    historical standards for radical cystectomy, 110-111
    modern radical cystectomy, 111-112
    modern radical cystectomy outcome, 114-118
    patient selection factors, 119
    standardization, 118-119
  progression of, molecular alterations associated with, 75-83
  quality of life in organ preservation, 132
  radiation therapy for, 130
  regimens for "unfit" patients, 137
  role of molecular profiling in, 140-141
  second-line therapy for, 139
  single-institution data with radiosensitizers, 131-132
  staging, prognostic features, and outcomes, 87-89
  stimulating T cells for cancer immunotherapy, 167-170
  superficial, advances in management of, 85-94
  superficial recurrence in organ preservation, 132-133
  T-cell activation and costimulatory signals, 167
  transurethral resection for, 129-130
  treatment, 89-91
  triple-drug combination chemotherapy, 137-138
  unfit, elderly and renal impaired patients with, 138-139
  urinary marker tests, 86-87
Bladder preservation
  multimodality therapy for muscle invasive bladder tumor, 129-133
  perioperative chemotherapy in muscle-invasive bladder cancer for, 122-127
Bone metastases, surgical therapy of, 206-214
  humerus, 210-211
  long bone, 207, 209-210
  minimally invasive and novel procedures, 213-214
  pelvis, 211-212
  spine, 212-213
  surgical goals, 207
Bortezomib, for advanced urothelial cancer, 158-159

Bowel segment, in urinary diversion, 98-100
BRAF pathway, in melanoma, 548-549
Brain metastasis, surgical therapy in
  complications of, 201
  epidemiology, 197
  evolution of strategies in, 198
  incidence and distribution, 197-198
  local therapies with, 203
  number of lesions, 200
  prognostic factors and patient selection, 198-199
  rationale, 198
  single metastasis, 200
  stereotactic radiosurgery, 201, 203
  techniques in, 199-200
  treatment strategies for, recurrence of, 200-201
  tumor histology, 200
BRCA1 gene
  biology of, in hereditary breast cancer
    DNA repair and mutation, 380-381
    pathology associated with germ-line mutations, 379-380
    protein functions, 381-382
  versus BRCA2, different hormonal effects on, for hereditary breast cancer prevention, 404
  in breast cancer chemotherapy, 387
  in breast cancer radiotherapy, 387-389
  in hereditary gynecologic cancers
    chemoprevention of, 407
    screening of, 406-407
    use of salpingo-oophorectomy, 407
  mammography-based screening, 393
  mutations of, in breast cancer, 239
  negative, hereditary breast cancer, RRSO role in, 408
  prognosis for hereditary breast cancer treatment, 384-387
BRCA2 gene
  biology of, in hereditary breast cancer
    DNA repair and mutation, 380-381
    pathology of germ-line mutations, 379-380
    protein function, 381-382
  versus BRCA1, different hormonal effects on, for hereditary breast cancer prevention, 404
  in breast cancer chemotherapy, 387
  in breast cancer radiotherapy, 387-389
  germline mutation, as high-risk group for pancreatic cancer detection, 289
  in hereditary gynecologic cancers
    chemoprevention of, 407
    screening of, 406-407
    use of salpingo-oophorectomy, 407
  mutations of, in breast cancer, 239
  negative, hereditary breast cancer, RRSO role in, 408
  prognosis for hereditary breast cancer treatment, 384-387
Breast, small cell carcinoma of, 65-66
Breast cancer
  and Cowden syndrome, 429-430
  general considerations in surgical therapy, 234-235
  hereditary, *see* Hereditary breast cancer
  surgical management
    axillary evaluation, 237-238
    BRCA1 and BRCA2 mutations, 239
    breast cancer in pregnancy, 238-239
    ductal carcinoma in situ, 237
    high-risk breast lesions, 235-237
    male breast cancer, 238
Breast carcinoma, in lung metastases, 190
Breast lesion, surgical therapy for, 235-237

Cancer, hereditary predisposition to, 367-368
Capecitabine, chemoradiation based on, for locally advanced pancreatic cancer, 342
CDKN2A locus, in patients with family history of melanoma, 453
  germline mutations of, 454-455
Cetuximab, for targeted pancreatic cancer therapy, 357
Chemoradiation
  future strategies in pancreatic cancer, 335-345
    diagnosis and staging, 335-336
    downstaging, 343-344
    IMRT and stereotactic therapy, 344-345
    multidisciplinary management in, 336-339
    novel approaches, 341-343
    principles, 340-341
  for locally advanced pancreatic cancer, 329-332
  for pancreatic cancer, 323
Chemotherapy, *see also* Adjuvant chemotherapy; Neoadjuvant chemotherapy
  as adjuvant therapy for pancreatic cancer, 323-324
  cytotoxic, *see* Cytotoxic chemotherapy
  for hereditary breast cancer
    prevention, 403
    treatment, 387
  for metastatic or unresectable bladder cancer, 135-141
  postoperative, for ovarian cancer, 232-233
  preoperative, for colorectal metastasis, 180-181
  randomized trial in melanoma, 512
  for small cell carcinoma of gastrointestinal tract, 47-48
    of uterine cervix, 60
Chest radiography, for diagnosis of lung metastases, 187
Colon cancer
  MYH and *MSH6* mutations in
    familial adenomatous polyposis, 418-419
    Lynch syndrome, 421-423
    polyposis associated with, 419-421
Colorectal cancer
  familial, *see* Familial colorectal cancer
  hereditary nonpolyposis, *see* Hereditary nonpolyposis colorectal cancer
  and sporadic adenomas, on hereditary nonpolyposis colorectal cancer identification, 412
Colorectal carcinomas, in lung metastases, 189-190
Colorectal liver metastasis, surgical therapy of
  patient selection, 178
  preoperative chemotherapy, 179-180
  radiofrequency ablation, 180-181
  regional chemotherapy, 181
  resectability in, 179
Computed tomography, chest, for diagnosis of lung metastases, 187
Continent cutaneous diversion, for urinary diversion, 103
Co-stimulatory signals, in high-risk bladder cancer, 167
Cowden syndrome, 428-433
  breast cancer and, 429-430
  genetic counseling for, 431-432
  management, 430-431
  nonmalignant manifestations of, 430
  other malignancies associated with, 430
  PTEN in, 432-433
  surveillance of, 431
Cranial irradiation, prophylactic, for laryngeal small cell carcinoma, 6-7
Cytokinesis, and BRCA1 and BRCA2 in hereditary breast cancer, 382
Cytoreductive surgery, for malignant peritoneal disease, 217-219
Cytotoxic chemotherapy
  for metastatic melanoma
    alkylating agents, 532-535
    platinum compounds, 536
    taxanes, 535-536
    vinca alkaloids, 536
Cytotoxic therapy
  for advanced pancreatic adenocarcinoma, 347-352
    anti-folate agents, 350
    docetaxel, 350
    fluoropyrimidine therapy, 347-348

Cytotoxic therapy (*Continued*)
gemcitabine, 348-350
multiple drug combinations, 350-351
second-line therapies, 350
topoisomerase-1 inhibitor, 350

Diabetes
and early detection of pancreatic cancer
on glucose intolerance, 290
as marker of diagnosis, 290-291
on new-onset of disease, 291
on resectable disease, 291
DNA repair, of BRCA1 and BRCA2 in hereditary breast cancer, 380-381
DNA repair modulation
in metastatic melanoma
base excision repair, 541
mismatch repair pathway, 541
O^6-methylguanine-DNA methyltransferase, 540-541
Docetaxel, for advanced pancreatic adenocarcinoma, 350
Ductal carcinoma in situ, surgical therapy for, 237

EGFR, *see* Epidermal growth factor receptor
Endometrium, small cell carcinoma of, 61
Epidermal growth factor receptor
targeted in pancreatic cancer, 356-358
cetuximab, 357
erlotinib, 357-358
Epigenetic markers, for early detection of pancreatic cancer, 306
Epithilones, for advanced urothelial cancer, 160
Erlotinib, for targeted pancreatic cancer therapy, 357-358
Extrapulmonary small cell carcinoma, 1
clinical behavior, 33
diagnosis, 31-32
differential diagnosis, 32
histogenesis, 30
molecular alterations, 32-33
sites of occurrence, 31

Fallopian tube, undifferentiated small cell carcinoma of, 62
Familial adenomatous polyposis
in colon cancer predispositions, 418-419
MYH-associated, in colon cancer predisposition identification, 419-421
clinical management, 421
estimated CRC risk, 419-420
genetic testing, 420-421
Familial atypical multiple mole melanoma syndrome, as high-risk group for pancreatic cancer detection, 289
Familial colorectal cancer
syndrome X in
clinical features, 425-426
etiology, 426-427
Familial pancreatic cancer, as high-risk group for cancer detection, 289-290
Farnesyl transferase inhibitors, for targeted pancreatic cancer therapy, 356
Fas, in the molecular basis of melanomagenesis and the metastatic phenotype, 479-480
Female genital tract, small cell carcinoma of
endometrium, 61
ovary, 61-62
undifferentiated carcinoma of fallopian tube, 62
uterine cervix, 58-59
chemotherapy, 60
clinical features, 59
epidemiology, 59
local control, 60
microscopic pathology, 59
prognostic features, 60
recurrence, 61
treatment, 59-60
whole-brain radiation, 60
Female genital tract, small cell carcinoma of (*Continued*)
vagina, 62-63
vulva, 63
Fibroblast growth factor
in melanoma
alteration of receptor, 548
basic, 485
stimulation of angiogenesis, 556
Fluoropyrimidine therapy
for advanced pancreatic adenocarcinoma, 347-348
and gemcitabine, 348-349
5-Fluorouracil chemotherapy
for locally advanced pancreatic cancer
chemoradiation with, 340-341
and radiation therapy, 329

Gastrointestinal stromal tumor
adjuvant therapy, 265
metastatic/recurrent, 266-267
neoadjuvant therapy, 265-266
technical aspects of resection
general aspects, 264-265
laparoscopy, 265
pretreatment biopsy, 265
Gastrointestinal tract, small cell carcinoma of, 43-49
clinical management, 47
clinical presentation, 44
epidemiology, 43-44
etiology, 45-46
pathology, 44-45
prognosis, 48
staging, 44
treatment
chemotherapy, 47-48
radiation therapy, 48
surgery, 47
Gemcitabine
for advanced pancreatic adenocarcinoma
fixed dose rate, 348
and fluoropyrimidine, 348-349
and platinum combinations, 349-350
single-agent, 348
for locally advanced pancreatic cancer
chemoradiation with, 341-342
and radiation therapy, 329-330
Genetic counseling
for Cowden syndrome, 431-432
practical delivery for cancer risk assessment, 369-377
fundamentals, 370-373
provision of services for, 373-376
Genetic markers, for early detection of pancreatic cancer, 305-306
Genetic predisposition, of cancer, recognition and management, 367-368
Genetic testing
ethical and legal aspects of, for cancer
autonomy, 435-436
beneficence, 439-440
biomedical ethics in moral theory, 435
equity, 441
informed consent and fidelity, 441-442
nonmaleficence, 436-439
paternalism, 440-441
special nature of information, 435
veracity, 441
in patients with a family history of melanoma, 456-457
Genital tract, female, small cell carcinoma of
endometrium, 61
ovary, 61-62
undifferentiated carcinoma of fallopian tube, 62

Genital tract, female, small cell carcinoma of (*Continued*)
uterine cervix, 58-59
chemotherapy, 60
clinical features, 59
epidemiology, 59
local control, 60
microscopic pathology, 59
prognostic features, 60
recurrence, 61
treatment, 59-60
whole-brain radiation, 60
vagina, 62-63
vulva, 63
Germ cell tumors, in lung metastases, 190-191
Germline mutation
of BRCA1 and BRCA2 in hereditary breast cancer, 379-380
BRCA2 gene, as high-risk group for pancreatic cancer detection, 289
Gynecologic cancers, in lung metastases, 191-192

Halichondrin B analog, for advanced urothelial cancer, 161
Head and neck carcinomas, in lung metastases, 191
Head and neck small cell carcinoma, 3-9
larynx, 5-6
treatment, 6-7
nose, 9-10
paranasal sinuses, 9-10
salivary glands, 7-8
thyroid gland, 10-11
Hereditary breast cancer
biology of BRCA1 and BRCA2 in
DNA repair and mutations, 380-381
pathology associated with germ-line mutations, 379-380
protein function, 381-382
BRCA-negative, RRSO role in, 408
prevention of
chemotherapy, 403
hormonal effects on BRCA1 and BRCA2 carriers in, 404
individuals at risk, 401
lifestyle modifications, 404
prophylactic mastectomy, 401
risk-reducing bilateral salpingo-oophorectomy, 402-403
in screening and prevention of hereditary gynecologic cancer, 406
screening of, 392-399
areas for further research, 398-399
current recommendations, 398
magnetic resonance imaging, 393-398
mammography, 393
psychological effects, 398
technical considerations, 398
ultrasound, 393
treatment of
BRCA prognosis, 384-387
response to chemotherapy, 387
response to radiotherapy, 387-389
Hereditary gynecologic cancer
screening and prevention of
hereditary breast and ovarian cancer, 406
hereditary nonpolyposis colorectal cancer/Lynch syndrome, 408-409
risk reduction for BRCA1 and BRCA2 mutations, 406-408
role of RRSO in, 408
Hereditary nonpolyposis colorectal cancer
approach for identification of, 411-416
adenoma–carcinoma hypothesis, 412
immunohistochemistry, 414
microsatellites and its instability, 413-414
mismatch repair genes, 413
MMR mutation testing, 416
patient selection for, 415-416
population testing for, 414-415
Hereditary nonpolyposis colorectal cancer (*Continued*)
gynecologic cancer screening in, 408-409
as high-risk group for pancreatic cancer detection, 289
MYH and *MSH6* mutations in, 421-423
atypical form of, 422
clinical management, 422-423
gene in, 422
genetic testing for, 422
risk-reducing surgery in, 409
Hereditary ovarian cancer
risk-reduction on BRCA1 and BRCA2 mutations
chemoprevention of, 407
screening of, 406-407
use of salpingo-oophorectomy, 407-408
High-throughput transcript profiling
using clinical specimens for bladder cancer, microarrays for progression target discovery, 81-82
using in vitro models for bladder cancer, 78-79
Humeral metastases, surgical therapy for, 210-211

Ileal conduit, for urinary diversion, 102
Imaging tests, as screening strategies for pancreatic adenocarcinoma, 298-299
Immunohistochemistry, on hereditary nonpolyposis colorectal cancer identification, 414
Immunotherapy, vaccine-based approaches, as targeted agents in pancreatic cancer, 360
IMRT, *see* Intensity-modulated radiation therapy
Innate immunity, in high-risk bladder cancer, 165-166
Integrins, stimulation of angiogenesis in melanoma, 558-560
Intensity-modulated radiation therapy, for pancreatic cancer, 344-345
Interferon-alpha
randomized trial in melanoma
individual data, 512-513
reviews/meta-analysis, 513
Interleukin-8, stimulation of angiogenesis in melanoma, 557
Intraperitoneal hyperthermic chemoperfusion, for malignant peritoneal disease, 218-219

Kidney, small cell carcinoma of, 68-69
KIT
in melanoma
inhibition, 551
mutations, 547-548

Laminin, in melanomagenesis, 486
Larynx, small cell carcinoma of, 5-6
treatment, 6
prophylactic cranial irradiation, 6-7
Lifestyle, on hereditary breast cancer prevention, 404
Liver resection, for liver metastases, 177-178
Long bone metastases, surgical therapy of, 207, 209-210
Lung cancer, primary, surgical therapy of
bronchoscopy, 251
concerns unique to VATS lobectomy, 253-254
extent of pulmonary resection in, 251
needle biopsy *versus* wedge resection, 250-251
open *versus* video-assisted thoracic surgery lobectomy, 252-253
preoperative assessment, 250
robotics and general thoracic surgery, 254
sleeve lobectomy, 252
VATS lobectomy, 252-253
VATS *versus* thoracotomy for lobectomy, 253
video-assisted mediastinoscopy, 251
wedge resections, 251-252
wedge resections with brachytherapy, 252
Lung metastases
assessment and prognostication
complete *versus* incomplete resection, 188
disease-free interval, 188

Lung metastases (*Continued*)
lymph node status, 188
number of lesions, 188
repeat pulmonary metastasectomy, 188
tumor "resectability," 188
diagnostic methodology
chest computed tomography, 187
chest radiography, 187
molecular markers, 187-188
positron emission tomography scanning, 187
outcome by tumor type
breast carcinoma, 190
colorectal carcinomas, 189-190
germ cell tumors, 190-191
gynecologic cancers, 191-192
head and neck carcinomas, 191
melanoma, 190
osteogenic sarcoma, 189
renal carcinoma, 191
soft tissue sarcoma, 189
surgical approach and resection, 192-193
surgical therapy for, 186-193
Lymph node dissection
for cutaneous melanoma, 273-274
elective, randomized trial in melanoma, 510
Lymph nodes, regional
in melanoma, management of
biopsy technique for, 501-503
biopsy trial for, 503-504
distant metastatic resection, 505
evolution of sentinel lymph node biopsy, 500
ongoing biopsy research, 504-505
selection criteria, 500-501
Lymphadenectomy
extended, for surgical management of pancreatic adenocarcinoma, 314-315
optimal surgical standard for invasive bladder cancer, 110-119
Lymphokine-activated killer cells, early, in adoptive cell transfer therapy for metastatic melanoma, 524-525
Lynch syndrome, in colon cancer predisposition identification, 421-423

Magnetic resonance imaging
for hereditary breast cancer screening, 393-398
clinical studies of, 395-396
cost-effectiveness of, 397-398
and mortality reduction, 396-397
Male breast cancer, surgical therapy for, 238
Malignant peritoneal disease, surgical therapy of
complications of CS/IPHC, 218
cytoreductive surgery principles, 217
intraperitoneal hyperthermic chemoperfusion principles, 218
malignant pleural effusions
drainage-based methods, 220
evaluation, 219-220
mechanical techniques of sclerosis, 222
pleuroperitoneal shunting, 220-221
sclerosis-based pleural effusion management, 221
small catheter drainage, 220
techniques of sclerosis-talc and chemical sclerosis, 221-222
treatment concepts, 220
natural history, 215-216
palliative surgery
malignant ascites, 216
malignant obstruction, 216-217
patient selection for CS/IPHC, 218
patterns of tumor dissemination, 215
prognosis and future trends, 222
results of CS/IPHC, 219
Malignant peritoneal disease, surgical therapy of (*Continued*)
therapeutic cytoreductive surgery/intraperitoneal hyperthermic chemoperfusion, 217
Malignant pleural effusions, surgical therapy of, 219-222
Mammography
for hereditary breast cancer screening
BRCA1-related tumors, 393
breast density, 393
tumor doubling time, 393
Mastectomy, prophylactic, for hereditary breast cancer prevention, 401
Matrix metalloproteinase inhibitors, for targeted pancreatic cancer therapy, 355-356
Matrix metalloproteinases, in melanoma angiogenesis, 560-561
molecular basis of, 484-486
basic fibroblast growth factor, 485
laminin and extravascular migratory metastasis, 486
p75 nerve growth factor receptor and brain metastases, 485
MEK inhibition, in melanoma, 551
MEK pathway, in melanoma, 549
Melanoma, 449-451
2001 revision of American Joint Committee on Cancer staging system for, 491-496
controversies, 492-493, 494
the current system, 491-492
potential new prognostic factors for consideration in next revision, 493, 495
adjuvant therapy trials in
surgical procedures, 509-512
systemic therapies, 512-513
angiogenesis in, growth factors stimulation on, 556-563
cutaneous, surgical therapy of
excision, 270-273
in lung metastases, 190
lymph node dissection for clinically evident regional metastases, 273-274
regional management of the clinically node-negative patient, 274-276
satellite lesions and in-transit metastases, 276-277
distant metastatic, resection of, 505
failure of senescence from dysplasia to, 467-474
four patterns of vertical growth, 469
malignant transformation, 468
maturation, 469
origin of new paradigm, 468
sequence, 468-469
three premises for new paradigm, 468
tissue microarray, 469-473
genetics of patients with family history of, 452-458
advice about sun exposure, 458
CDKN2A germline mutations, 454-455
CDKN2A locus, 453
familial and atypical moles, 455-456
gene testing, 456-457
other high-risk susceptibility genes, 453-454
risk of other cancers, 455
skin color determination, 457-458
metastatic, cutaneous, surgical therapy of
brain and spinal cord, 278
gastrointestinal tract, 278
liver, 277-278
lung, 277
soft tissue, 277
metastatic, management of
biochemotherapy, 536-538
clinical trial end points, 541-542
cytotoxic chemotherapy, 532-536
DNA repair modulation, 540-541
targeted agents, 538-539
molecular basis of
cell cycle dysregulation and malignant phenotype of, 476-479
cell proliferation markers, 481-483

Melanoma, 449-451 (*Continued*)
cell–matrix interactions, 483-484
comparative genomic hybridization and DNA copy number changes, 481
instability in compound nevus of Spitz, 481
matrix metalloproteinases, 484-486
mutations in sun- and non–sun-exposed skin, 480
oncogenes and proto-oncogenes, 480
p53, *bcl-2*, Fas, telomerase and the apoptotic pathways, 479-480
overview of research in
appendix, 575
basic, 566-570
clinical, 570-572
epidemiology and prevention, 572-574
training, 574-575
pathways in, 546-552
alterations in upstream compartment, 547-548
downstream compartment, 548-549
KIT inhibition, 551
MEK inhibition, 551
PTEN-PI3K-AKT, 551
target agents for, 549-550
prevention and early detection of
early childhood sun exposure, 461-462
early screening, 462
patient care optimization, 464-465
patient self-examinations, 464
physician screening, 462-463
primary strategies, 460-461
public education, 464
risk stratification and cost-effectiveness, 463-464
screening tests, 463
secondary strategies, 462
sun tanning behaviors, 462
sunscreens, 461
primary, wide excision of, 498-500
vaccines
obstacles to effective immunizations, 516-517
results of phase III randomized trials, 518-521
ways of cell avoidance of T cell detection, 517-518
Merkel cell carcinoma
clinical presentation, 53-54
epidemiology, 53
follow-up measures, 56
therapeutic options
for stage I, 54-56
for stage II, 56
for stage III, 56
tumor biology, 52-53
Mesenteric veins, portal and superior, resection for surgical management of pancreatic adenocarcinoma, 315-316
Microarray technologies, for identification of molecular targets involved in bladder cancer progression, 77
MicroRNA alterations, for early detection of pancreatic cancer, 306-307
Microsatellite instability, on hereditary nonpolyposis colorectal cancer identification, 413-414
Mismatch repair genes, on hereditary nonpolyposis colorectal cancer identification, 413
Mitogen-activated protein kinase inhibitors, as targeted agents in pancreatic cancer, 359
MMR gene, on hereditary nonpolyposis colorectal cancer identification, 416
Molecular alterations
association with bladder cancer progression, 75-83
high-throughput transcript profiling
bladder cancer specimens for, 79-82
in vitro models of bladder cancer, 78-79
identification of molecular targets with microarray technologies, 77
in oncogenes and tumor suppressor genes in bladder cancer progression, 77
as target treatment for bladder cancer, 73-74
Molecular markers
for diagnosis of lung metastases, 187-188
identification of, for the early detection of pancreatic neoplasia, 303-307
as screening strategies for pancreatic adenocarcinoma, 299-300
Molecular targeted therapy, for locally advanced pancreatic cancer, 342-343
Monoclonal antibodies, for targeted pancreatic cancer therapy, 355
MSH6 gene
mutation in
familial adenomatous polyposis, 418-419
Lynch syndrome, 421-423
M-VAC regimen, for metastatic or unresectable bladder cancer, 135-136
MYH gene
mutation in
familial adenomatous polyposis, 418-419
Lynch syndrome, 421-423
polyposis associated with, 419-421

Neoadjuvant chemotherapy
for bladder preservation in muscle-invasive bladder cancer, 122-127
for pancreatic cancer, 324-325
Neoadjuvant therapy
for gastrointestinal stromal tumor, 245-246
for rectal cancer, 245-246
Neuroendocrine liver metastases, surgical therapy of, 181-182
Non-bilharzial squamous cell carcinoma, management of, 145-146
Non-neuroendocrine, non-colorectal liver metastases, surgical therapy of, 182-183
Non-urachal adenocarcinoma, management of, 147-148
Nose, small cell carcinoma of, 9-10

O^6-methylguanine-DNA methyltransferase, in metastatic melanoma, 540-541
Oblimersen sodium, for metastatic melanoma, 539
Oncogenes
in bladder cancer progression, 77
in the melanomagenesis and the metastatic phenotype, 480
Orthotopic neobladder, for urinary diversion, 103
Osteogenic sarcoma, in lung metastases, 189
Ovarian cancer
hereditary, *see* Hereditary ovarian cancer
screening and prevention of, and hereditary breast cancer, 406
surgical therapy of
approaches in, 229-232
general considerations in adnexal mass management, 227-228
histology and embryology of the ovary, 226-227
postoperative chemotherapy, 232-233
preoperative evaluation and preparation of patients with adnexal mass management, 228-229
Ovary, small cell carcinoma of
clinical features, 61
differential diagnosis, 62
gross pathology, 61
microscopic pathology, 61-62
treatment, 62

p53, in the molecular basis of melanomagenesis and the metastatic phenotype, 479-480
Palliation, for surgical management of pancreatic adenocarcinoma, 316-317
Palliative surgery, for malignant peritoneal disease, 216-217
Pancreatic adenocarcinoma
advanced, cytotoxic therapy for, 347-352
anti-folate combinations, 350
docetaxel, 350
fluoropyrimidine therapy, 347-348
gemcitabine, 348-350
multiple drug combinations, 350-351
second-line therapies, 351-352
topoisomerase-1 inhibitor, 350

Pancreatic adenocarcinoma (*Continued*)
screening in high-risk patients, 295-301
candidates for, 296-297
diagnostic yield of, 300
early stages, 295-296
frequency of, 300
genetic counseling, 298
mean age for, 297-298
strategies for, 298-300
surgical management of, 311-318
extended lymphadenectomy, 314-315
outcomes, 317
palliation, 316-317
pancreatic-enteric anastomosis, 316
portal and superior mesenteric vein resection, 315-316
preoperative diagnosis and staging, 312-314
prognostic factors and survival, 317
standard *versus* pylorus-preserving pancreaticoduodenectomy, 316
Pancreatic cancer, 283, 284-292
adjuvant therapy for, 321-325
chemoradiation, 323
chemotherapy, 323-324
evolving therapy, 325
historic studies, 322-323
neoadjuvant therapy, 324-325
rationale, 322
surgical resection, 321-322
detection of
definition(s), 285
diagnostic confirmation in, 292
mortality, 284-285
progression, 285-288
screening approaches, 288-292
future chemoradiation strategies in, 335-345
diagnosis and staging, 335-336
downstaging of, 343-344
IMRT and stereotactic therapy, 344-345
molecular targeted therapy, 342-343
multidisciplinary management in, 336-339
novel approaches for, 341-343
principles in, 340-341
future targeted therapies
in angiogenesis, 358-359
bevacizumab, 359
developments, 354-355
early examples of, 355-356
EGFR pathway, 356-358
other attractive targets, 359-360
and tailored patient management in, 354-361
locally advanced, 327-332
chemoradiation for unresectable disease, 329-332
radiation and targeted therapies, 331-332
radiation strategies, 331
radiation therapy and 5-fluorouracil chemotherapy, 329
molecular markers for early detection of, 303-307
recent developments, 304-307
targeting high-risk groups, 303-304
"patient-tailored" approach for, 360-361
Pancreatic juice, for early detection of pancreatic cancer, 305
Pancreaticoduodenectomy
standard *versus* pylorus-preserving, for surgical management of pancreatic adenocarcinoma, 316
morbidity and mortality after, 317
Pancreatitis, hereditary, as high-risk group for pancreatic cancer detection, 289
Paranasal sinuses, small cell carcinoma of, 9-10
Pelvic metastases, surgical therapy for, 211-212
Pemetrexed, for advanced urothelial cancer, 159-160
Peutz-Jeghers syndrome, as high-risk group for pancreatic cancer detection, 289
PI3K-AKT pathway, in melanoma, 549
Placental growth factor, stimulation of angiogenesis in melanoma, 556-557
Plasminogen, stimulation of angiogenesis in melanoma, 557-558
Platinum agents
and gemcitabine, for advanced pancreatic adenocarcinoma, 349-350
for metastatic melanoma, 536
Pleura, small cell carcinoma of, 68
Population testing, in identifying hereditary nonpolyposis colon cancer, 414-415
Positron emission tomography scanning, for diagnosis of lung metastases, 187
Prophylactic cranial irradiation, for laryngeal small cell carcinoma, 6-7
Prostate gland, small cell carcinoma, 22-28
clinical presentation, 24
diagnosis, 24-25
histology, 23
prognosis, 27
staging, 25-26
treatment, 27
Proteomics, for early detection of pancreatic cancer, 305
Proteosomal inhibitors, as targeted agents in pancreatic cancer, 359-360
Proto-oncogenes, in the melanomagenesis and the metastatic phenotype, 480
PTEN gene, in Cowden syndrome, 432-433
PTEN pathway, in melanoma, 549
PTEN-PI3K-AKT pathway, in melanoma, 551

Quality of life, after urinary diversion, 104-105

Radiation therapy
for locally advanced pancreatic cancer, 331
and 5-fluorouracil chemotherapy, 329
and gemcitabine chemotherapy, 329-330
and targeted therapies, 331-332
for small cell carcinoma
of gastrointestinal tract, 48
of larynx, prophylactic cranial irradiation, 6-7
of uterine cervix, whole-brain radiation, 60
Radical cystectomy
modern surgical procedure
contemporary surgical techniques, 111-112
normal lymphatic drainage of the bladder, 111
relevant surgical anatomy, 111
optimal surgical standard for invasive bladder cancer, 110-119
Radiofrequency ablation, for colorectal metastasis, 180-181
Radiotherapy, for hereditary breast cancer treatment, 387-389
RAS pathway, alteration in melanoma, 548
Rectal cancer, surgical therapy of
adjuvant/neoadjuvant therapy
indications, 245
preoperative *versus* postoperative radiation, 245-246
diagnosis and staging, 241-242
functional outcome
continence, 246
urinary and sexual function, 247
recurrence, 246
surgical considerations
distal margins, 243-244
radial margins, 243
surgical procedures
abdominoperineal resection, 244
ileostomy and colostomy, 244-245
low anterior resection, 244
minimally invasive surgery, 245
pelvic exenteration, 244
Regional chemotherapy, for colorectal metastasis, 181

Renal carcinoma, in lung metastases, 191
Retroperitoneal soft tissue sarcoma
  metastatic/recurrent, 263
  technical aspects of resection
    adjuvant therapy, 262
    general aspects, 261
    laparoscopy, 262
    neoadjuvant therapy, 262-263
    pretreatment biopsy, 261-262
Risk assessment, cancer, practical aspects of delivering genetic counseling for, 369-376
Risk-reducing salpingo-oophorectomy
  prevention for hereditary breast cancer, 402-403
  in screening and prevention of hereditary gynecologic cancers, 407-408
RTK
  alterations in melanoma
    fibroblast growth factor receptor, 548
    KIT mutations, 547-548
    RAS, 548

Salivary glands, small cell carcinoma of, 7-8
Satraplatin, for advanced urothelial cancer, 160
Sentinel lymph node biopsy
  for melanoma
    management of regional lymph nodes, 500-505
    randomized trial in, 510-511
    wide margin of excision, 498-500
Serum markers, for early detection of pancreatic cancer, 304-305
Skin color, genes determining, among patients with a family history of melanoma, 457-458
Small cell carcinoma
  of bladder
    clinical features, 16
    diagnosis, 16-17
    epidemiology, 15
    histology, 15-16
    prognosis, 19
    staging, 17
    treatment, 17-19
  of breast, 65-66
  extrapulmonary, 1
    clinical behavior, 33
    diagnosis, 31-32
    differential diagnosis, 32
    histogenesis, 30
    molecular alterations, 32-33
    sites of occurrence, 31
  of gastrointestinal tract, 43-49
    clinical management, 47
    clinical presentation, 44
    epidemiology, 43-44
    etiology, 45-46
    pathology, 44-45
    prognosis, 48
    staging, 44
    treatment, 47-48
  of head and neck, 3-9
    larynx, 5-7
    nose, 9-10
    paranasal sinuses, 9-10
    salivary glands, 7-8
    thyroid gland, 10-11
  of kidney, 68-69
  of pleura, 68
  of prostate, 22-28
    clinical presentation, 24
    diagnosis, 24-25
    histology, 23
Small cell carcinoma (*Continued*)
    prognosis, 27
    staging, 25-26
    treatment, 27
  of thymus, 69
  of unknown primary
    cytogenetics, 40
    diagnosis, 40
    histology, 39-40
    presentation, 40
    prognosis, 40-41
    staging, 40
    treatment, 40-41
    tumor biology, 40
Small cell carcinoma, management of, 148-149
Soft tissue sarcoma
  local management of, 256-267
    clinical assessment of, 257
    extremity, 258-259
    gastrointestinal stromal tumor, 264-267
    head and neck, 259-261
    prognostic factors for, 257-258
    retroperitoneal, 261-263
  in lung metastases, 189
Sorafenib
  in melanoma
    on BRAF mutation, 549-550
    metastatic, 538-539
Spinal metastases, surgical therapy for, 212-213
Sporadic adenoma, and colorectal carcinoma, on hereditary nonpolyposis colorectal cancer identification, 412
Standardization, surgical, of radical cystectomy and lymphadenectomy for invasive bladder cancer, 110-119
Stem cell, differentiation of, BRCA1 and BRCA2 in hereditary breast cancer in, 381-382
Stereotactic radiosurgery, for brain metastasis, 201, 203
Stereotactic radiotherapy, for pancreatic cancer, 344-345
SU11248 (Sunitinib), for advanced urothelial cancer, 157-158
Suberoylanilide hydroxamic acid, for advanced urothelial cancer, 159
Sun exposure, risk factor for melanoma, 458
Sun tanning, and melanoma, 462
Sunscreens, role in melanoma prevention, 461
Surgery, for small cell carcinoma of gastrointestinal tract, 47
Surgical oncology, 175-176
Surgical therapy
  of bone metastases, 206-214
    humerus, 210-211
    long bone, 207, 209-210
    minimally invasive and novel procedures in, 213-214
    pelvis, 211-212
    spine, 211-212
  in brain metastasis, 197-203
    complications in, 201
    evolution of surgical treatment strategies, 198
    local therapies with, 203
    rationale, 198
    surgical technique, 199-200
  of breast cancer, 234-239
  for colorectal liver metastases, 178-181
  of cutaneous melanoma, 270-278
  of liver metastases, 177-178
  of lung metastases by tumor type
    breast carcinoma, 190
    colorectal carcinomas, 189-190
    germ cell tumor, 190-191
    gynecologic cancers, 191-192
    head and neck carcinomas, 191
    melanoma, 190
    osteogenic sarcoma, 189

Surgical therapy (*Continued*)
renal carcinoma, 191
soft tissue sarcoma, 189
of malignant peritoneal disease, 215-222
for melanoma
management of regional lymph nodes, 500-505
wide margin of excision, 498-500
neuroendocrine liver metastases, 181-182
non-neuroendocrine, non-colorectal liver metastases, 182-183
of ovarian cancer, 226-233
of primary lung cancer, 250-254
of rectal cancer
radical resection, 242-243
transanal endoscopic microsurgery, 242
transanal excision, 242
Syndrome X
in familial colorectal cancer
clinical features, 425-426
etiology, 426-427

Tamoxifen, on hereditary breast cancer prevention, alternatives to, 403
Taxanes, for metastatic melanoma, 535-536
T-cell activation, in high-risk bladder cancer, 167
TCR genes, with cell transfer, for metastatic melanoma, 529
Telemedicine, on practical delivery of hereditary cancer risk counseling, 376
Telomerase, in molecular basis of melanomagenesis and the metastatic phenotype, 479-480
Thymus gland, small cell carcinoma of, 69
Thyroid gland, small cell carcinoma of, 10-11
Tissue microarray
senescence in dysplasia-melanoma sequence using, 469-473
on advanced vertical growth, 473
on compound nevus, 470-471
on dysplastic nevus, 471
on early vertical growth, 472-473
on high-grade compound melanocytic dysplasia, 471-472
on intermediate vertical growth, 473
Topoisomerase-1 inhibitor, for advanced pancreatic adenocarcinoma, 350
Transcriptional regulation, of BRCA1 and BRCA2 in hereditary breast cancer, 381
Transforming growth factor-1, stimulation of angiogenesis in melanoma, 557
Tumor-infiltrating lymphocytes, for metastatic melanoma, 524-525
Tumor-suppressor genes, in bladder cancer progression, 77

Ultrasound, for hereditary breast cancer screening, 393
Undifferentiated small cell carcinoma, of fallopian tube, 62
Urachal adenocarcinoma, management of, 147-148
Ureter and renal pelvis cancer, management of, 149-151
Urinary continence, after urinary diversion, 104-105
Urinary diversion
bowel segment
gastric conduits or reservoirs, 99
ileal conduit or ileal-colic reservoirs, 98-99
jejunum conduit conduits or reservoirs, 99
continent cutaneous diversion, 103
ileal conduit, 102
options, patient selection and outcomes, 98-107
orthotopic neobladder, 103
patient selection criteria
ability to self-catheterize, 100-101
bowel pathology, 102
locally advanced and/or regionally metastatic cancer, 101-102
obesity, 101
patient age, 101
pelvic radiotherapy, 102
renal and hepatic function, 100
risk of urethral recurrence, 101
Urinary diversion (*Continued*)
surgical outcomes
cancer-related outcomes, 106
quality of life, 105-106
secondary malignancies, 107
surgery-related complications, 103-104
urinary continence and/or voiding dysfunction, 104-105
Urinary marker tests, for superficial bladder cancer, 86-87
Urothelial cancer
antifolates and antimetabolites, pemetrexed, 159-160
anti-microtubule agents
epothilones, 160
vinflunine, 160-161
cell cycle inhibitors, Bortezomib, 158-159
clinical trial design and patient selection issue
response measurement, 156-157
target measurement, 156
halichondrin B analog, E7389 (NSC#707389), 161
histone deacetylase inhibitors, suberoylanilide hydroxamic acid, 159
new molecular targets and novel agents for, 154-160
novel cytotoxic therapies, 159
platinum analogues, satraplatin, 160
selected targets and respective agents, angiogenesis inhibitors, 157
VEGF and VEGFR inhibitors
BAY 46-9006 (Sorafenib), 157-158
Bevacizumab, 157-158
SU11248 (Sunitinib), 157-158
Urothelial carcinoma
bilharzial bladder carcinoma, 146-147
cancers of the ureters and renal pelvis, 149-151
management of bladder cancers of non-transitional cell histology and ureter and renal pelvis cancer, 145-151
non-bilharzial squamous cell carcinoma, 145-146
non-urachal adenocarcinomas, 147-148
small cell carcinoma, 148-149
urachal adenocarcinomas, 148
Uterine cervix, small cell carcinoma of, 58-59
chemotherapy, 60
clinical features, 59
epidemiology, 59
local control, 60
microscopic pathology, 59
prognostic features, 60
recurrence, 61
treatment, 59-60
whole-brain radiation, 60

Vaccine
for melanoma
obstacles to effective immunization, 516-517
randomized trial of, 512
results of phase III randomized trials, 518-521
ways of cell avoidance of T cell detection, 517-518
Vagina, small cell carcinoma of
clinical features, 62
differential diagnosis, 63
gross pathology, 62
microscopic pathology, 62-63
treatment, 63
Vascular endothelial growth factor, stimulation of angiogenesis in melanoma, 556
Video-assisted thoracic surgery lobectomy, for primary lung cancer, 252-254
Vinca alkaloids, for metastatic melanoma, 536
Vinflunine, for advanced urothelial cancer, 160-161
Voiding dysfunction, after urinary diversion, 104-105
Vulva, small cell carcinoma of, 63

Whole-brain radiation, for small cell carcinoma of uterine cervix, 60